老年肝细胞癌患者的治疗现状

黄永杰; 吴德全; 苑俊辉

doi:10.3969/j.issn.1001-5256.2018.06.039

老年肝细胞癌患者的治疗现状

DOI: 10.3969/j.issn.1001-5256.2018.06.039

哈尔滨医科大学附属第二医院

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1702
- HTML全文浏览量: 13
- PDF下载量: 342
- 被引次数: 0
出版历程
- 收稿日期: 2018-01-23
- 出版日期: 2018-06-20

Current status of treatment of primary hepatocellular carcinoma in the elderly population

The Second Affiliated Hospital of Harbin Medical University

摘要

摘要: 随着全球老龄化加剧,老年人肝细胞癌(HCC)的发病率越来越高,使其成为一个全球性的健康问题。通过查阅大量相关文献分析了老年HCC患者的临床特点,综述了其治疗方法和疗效方面的现状。其中对疗效的评述主要是通过对世界上多个国家和地区的老年与非老年HCC患者治疗效果的对比体现的。指出HCC老年患者具有自身的临床特点,并且由于HCC老年患者常常合并其他疾病,如糖尿病、肾衰竭、肺和心血管疾病等,使得其治疗的风险增加,但是其疗效是肯定的。随着研究的深入,各种治疗方法的改进,老年人HCC的治疗效果也将提高,因此在临床工作中应采用积极的态度和策略治疗HCC老年患者。
- 癌,肝细胞 /
- 治疗 /
- 老年人 /
- 综述
Abstract: With the global aging, the incidence rate of HCC in the elderly population is gradually increasing, and thus it has become a global health issue. With reference to relevant literature, this article analyzes the clinical features of elderly HCC patients and reviews the current status of therapies and clinical outcomes. The review of clinical outcomes is mainly based on the comparison of therapeutic outcome between elderly and non-elderly HCC patients in many countries and regions in the world. This article points out that elderly HCC patients have their own clinical features, and since elderly HCC patients often have other diseases, such as diabetes, renal failure, and lung and cardiovascular diseases, there is an increase in the risk of treatment, but they often have positive treatment outcomes. With the deepening of research and the improvement of various treatment methods, the therapeutic outcome of elderly HCC patients will also be improved. Therefore, positive attitude and strategies should be adopted in the clinical treatment of elderly HCC patients.
- carcinoma, hepatocellular /
- therapy /
- aged /
- review

HTML全文

参考文献(47)

[1]WU BY, DONG HL, WANG ZX, et al.Effect of life table on of the average life expectancy from malignant tumors[J].Mod Prevent Med, 2015, 42 (23) :4328-4331. (in Chinese) 吴炳义, 董惠玲, 王在翔, 等.恶性肿瘤对平均预期寿命影响的生命表分析[J].现代预防医学, 2015, 42 (23) :4328-4331.

[2]STOTTER A, REED MW, GRAY LJ, et al.Comprehensive geriatric assessment and predicted 3-year survival in treatment planning for frail patients with early breast cancer[J].Br J Surg, 2015, 102 (5) :525-533.

[3]ZHENG R, ZENG H, ZHANG S, et al.National estimates of cancer prevalence in China, 2011[J].Cancer Lett, 2016, 370 (1) :33-38.

[4]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistic, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.

[5]MIRICI-CAPPA F, GRAMENZI A, SANTI V, et al.Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients:A 20-year multicentre experience[J].Gut, 2010, 59 (3) :387-396.

[6]LIANG HY, LU ZM.Current status and confusion in comprehensive interventional therapy for hepatocellular carcinoma[J].J Clin Hepatol, 2016, 32 (1) :44-48. (in Chinese) 梁宏元, 卢再鸣.原发性肝癌综合介入治疗现状与困惑[J].临床肝胆病杂志, 2016, 32 (1) :44-48.

[7]JIANG HT, CAO JY.Impact of laparoscopic versus open hepatectomy on perioperative clinical outcomes of patients with primary hepatic carcinoma[J].Chin Med Sci J, 2015, 30 (2) :80-83.

[8]OISHI K, ITAMOTO T, KOHASHI T, et al.Safety of hepatectomy for elderly patients with hepatocellular carcinoma[J].World J Gastroenterol, 2014, 20 (41) :15028-15036.

[9]IGUCHI T, SHIRABE K, AISHIMA S, et al.New pathologic stratification of microvascular invasion in hepatocellular carcinoma:predicting prognosis after living-donor liver transplantation[J].Transplantation, 2015, 99 (6) :1236-1242.

[10]LI Y.Early in patients with primary liver cancer treatment decision aid scheme of construction and application of research[D].Acad JSecond Military Med Univ, 2017. (in Chinese) 李玉.早期原发性肝癌患者治疗决策辅助方案的构建与应用研究[D].第二军医大学, 2017.

[11]LU LG.Advances in early screening and diagnosis of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1257-1261. (in Chinese) 陆伦根.原发性肝癌的早期筛查及诊断[J].临床肝胆病杂志, 2017, 33 (7) :1257-1261.

[12]WANG DD, WU LQ, WANG ZS.Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection:A matched study[J].Hepatobiliary Pancreat Dis Int, 2016, 15 (6) :626-632.

[13]GAO ZH, BAI DS, JIANG GQ, et al.Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma.[J].World J Hepatol, 2015, 7 (1) :40-43.

[14]HONDA T, MIYAAKI H, ICHIKAWA T, et al.Clinical characteristics of hepatocellular carcinoma in elderly patients[J].Oncol Lett, 2011, 2 (5) :851-854.

[15]COHEN MJ, BLOOM AI, BARAK O, et al.Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma[J].World J Gastroenterol, 2013, 19 (16) :2521-2528.

[16]KAO WY, CHIOU YY, HUNG HH, et al.Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy[J].J Clin Gastroenterol, 2012, 46 (1) :62-70.

[17]SU CW, LEI HJ, CHAU GY, et al.The effect of age on the longterm prognosis of patients with hepatocellular carcinoma after resection surgery:A propensity score matching analysis[J].Arch Surg, 2012, 147 (2) :137-144.

[18]NISHIKAWA H, ARIMOTO A, WAKASA T, et al.Surgical resection for hepatocellular carcinoma:Clinical outcomes and safety in elderly patients[J].Eur J Gastroenterol Hepatol, 2013, 25 (8) :912-919.

[19]REDDY SK, BARBAS AS, TURLEY RS, et al.Major liver resection in elderly patients:a multi-institutional analysis[J].J Am Coll Surg, 2011, 212 (5) :787-795.

[20]NISHIKAWA H, KIMURA T, KITA R, et al.Treatment for hepatocellular carcinoma in elderly patients:A literature review[J].J Cancer, 2013, 4 (8) :635-643.

[21]GUO ZQ, WANG QY, QI XS, et al.Recommendations for the diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases (2017) [J].J Clin Hepatol, 2017, 33 (12) :2275-2277. (in Chinese) 郭泽淇, 王倩怡, 祁兴顺, 等.《2017年美国肝病学会非酒精性脂肪性肝病诊疗指导》摘译[J].临床肝胆病杂志, 2017, 33 (12) :2275-2277.

[22]ZOU WL, GU XF.Analysis on the correlation of diabetes and IFG/IGT with NAFLD[J].Chin J Intradit West Med Liver Dis, 2017, 27 (6) :334-335. (in Chinese) 邹文兰, 顾学芳.2型糖尿病和糖代谢异常/糖耐量异常与非酒精性脂肪肝的相关性研究[J].中西医结合肝病杂志, 2017, 27 (6) :334-335.

[23]WANG LH, XIONG QF, YANG YF.Analysis of the clinical characteristics of primary liver cancer and the influencing factors of prognosis[J].Pract Geriatr, 2017, 31 (12) :1135-1137. (in Chinese) 王华利, 熊清芳, 杨永峰.279例老年原发性肝癌临床特点及预后影响因素分析[J].实用老年医学, 2017, 31 (12) :1135-1137.

[24]KESWANI RN, AHMED A, KEEFFE EB.Older age and liver transplantation:A review[J].Liver Transpl, 2004, 10 (8) :957-967.

[25]KIM J, KO ME, NELSON RA, et al.Increasing age and survival after orthotopic liver transplantation for patients with hepatocellular cancer[J].J Am Coll Surg, 2014, 218 (3) :431-438.

[26]XUE H.The decision tree model of liver resection and radiofrequency ablation in Milan standard[D].Acad J Second Military Med Univ, 2016. (in Chinese) 薛辉.米兰标准的老年肝癌肝切除与射频消融治疗的决策树模型[D].第二军医大学, 2016.

[27]CHANG M, HAO J.Laparoscopic hepatectomy for the treatment of senile primary small liver cancer clinical efficacy[J].Pop Sci Tech, 2015, 17 (12) :69-70. (in Chinese) 常明, 赫军.腹腔镜肝切除术治疗老年原发性微小肝癌的临床疗效[J].大众科技, 2015, 17 (12) :69-70.

[28]BOOTHE HW Jr.Current concepts in hepatobiliary surgery[J].Vet Clin North Am Small Anim Pract, 2015, 45 (3) :463-475.

[29]KAIBORI M, MATSUI K, ISHIZAKI M, et al.Hepatic resection for hepatocellular carcinoma in the elderly[J].J Surg Oncol, 2009, 99 (3) :154-160.

[30]MOHANTY S, BERLINER L, SHAH S.Surgical treatment for hepatocellular carcinoma[M]//An Information Technology Framework for Predictive, Preventive and Personalised Medicine.Springer International Publishing, 2015:1-15.

[31]YAMADA S, SHIMADA M, MIYAKE H, et al.Outcome of hepatectomy in super-elderly patients with hepatocellular carcinoma[J].Hepatol Res, 2012, 42 (5) :454-458.

[32]NOZAWA A, KUBO S, TAKEMURA S, et al.Hepatic resection for hepatocellular carcinoma in super-elderly patients aged 80years and older in the first decade of the 21st century[J].Surg Today, 2015, 45 (7) :851-857.

[33]SULPICE L, RAYAR M, CAMPILLO B, et al.Advanced age remains an Achilles heel for liver resections[J].World J Surg, 2013, 38 (4) :918-926.

[34]ZHAI YP, WANG HY, WANG Y, et al.Ultrasound-guided radiofrequency ablation for the treatment of elderly cancer of the liver and tumor residual risk factors[J].Chin J Gerontol, 2017, 37 (10) :2475-2477. (in Chinese) 翟渊鹏, 王海英, 王雁, 等.超声引导射频消融治疗老年肝癌的效果及肿瘤残留的危险因素[J].中国老年学杂志, 2017, 37 (10) :2475-2477.

[35]XIAO R, TIAN H, HU XD, et al.Influencing factors of microwave ablation on tumor-free survival rate in treatment of primary liver cancer[J].Hebei Med J, 2018, 40 (2) :277-279, 284. (in Chinese) 肖蓉, 田虹, 胡晓丹, 等.微波消融治疗老年原发性肝癌患者的无瘤生存影响因素分析[J].河北医药, 2018, 40 (2) :277-279, 284.

[36]de GIORGIO M, VEZZOLI S, COHEN E, et al.Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria[J].Liver Transpl, 2010, 16 (4) :503-512.

[37]TATEISHI R, SHIINA S, TERATANI T, et al.Percutaneous radiofrequency ablation for hepatocellular carcinoma[J].Cancer, 2005, 103 (6) :1201-1209.

[38]SATO M, TATEISHI R, YASUNAGA H, et al.Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma:A national survey of 54, 145 patients[J].J Gastroenterol, 2012, 47 (10) :1125-1133.

[39]NISHIKAWA H, KITA R, KIMURA T, et al.Transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma:Clinical outcome and safety in elderly patients[J].J Cancer, 2014, 5 (7) :590-597.

[40]CHEN J, JIN R, ZHAO J, et al.Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma[J].Cancer Lett, 2015, 367 (1) :1-11.

[41]ZHAO Y, LIU T, SHEN XJ, et al.Clinical analysis of advanced hepatocellular carcinoma patients treated with sorafenib[J].Chin J Curr Adv Gen Surg, 2015, 18 (8) :601-604. (in Chinese) 赵益, 刘涛, 沈象吉, 等.索拉非尼治疗中晚期肝细胞肝癌的临床分析[J].中国现代普通外科进展, 2015, 18 (8) :601-604.

[42]DI COSTANZO GG, TORTORA R, DE LM, et al.Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma[J].Med Oncol, 2013, 30 (1) :446.

[43]WONG H, TANG YF, YAO TJ, et al.The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC) [J].Oncologist, 2011, 16 (12) :1721-1728.

[44]JO M, YASUI K, KIRISHIMA T, et al.Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma[J].Hepatol Res, 2014, 44 (13) :1329-1338.

[45]IAVARONE M, CABIBBO G, PISCAGLIA F, et al.Field-practice study of sorafenib therapy for hepatocellular carcinoma:A prospective multicenter study in Italy[J].Hepatol, 2011, 54 (6) :2055-2063.

[46]MORIMOTO M, NUMATA K, KONDO M, et al.Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib[J].Hepatol Res, 2011, 41 (4) :296-302.

[47]EDELINE J, CROUZET L, LE SS, et al.Sorafenib use in elderly patients with hepatocellular carcinoma:caution about use of platelet aggregation inhibitors[J].Cancer Chemother Pharmacol, 2015, 75 (1) :215-219.

施引文献

资源附件(0)

访问统计